SK channels control the firing pattern of midbrain dopaminergic neurons in vivo.
A vast body of experimental in vitro work and modelling studies suggests that the firing pattern and/or rate of a majority of midbrain dopaminergic neurons may be controlled in part by Ca2+-activated K+ channels of the SK type. However, due to the lack of suitable tools, in vivo evidence is lacking. We have taken advantage of the development of the water-soluble, medium potency SK blocker N-methyl-laudanosine (CH3-L) to test this hypothesis in anaesthetized rats. In the lateral ventral tegmental area, CH3-L iontophoresis onto dopaminergic neurons significantly increased the coefficient of variation of their interspike intervals and the percentage of spikes generated in bursts as compared to the control condition. The effect of CH3-L persisted in the presence of a specific GABA(A) antagonist, suggesting a direct effect. It was robust and reversible, and was also observed in the substantia nigra. Control experiments demonstrated that the effect of CH3-L could be entirely ascribed to its blockade of SK channels. On the other hand, the firing pattern of noradrenergic neurons was much less affected by CH3-L. We provide here the first demonstration of a major role of SK channels in the control of the switch between tonic and burst firing of dopaminergic neurons in physiological conditions. This study also suggests a new strategy to develop modulators of the dopaminergic (DA) system, which could be of interest in the treatment of Parkinson's disease, and perhaps other diseases in which DA pathways are dysfunctional.
Waroux
Olivier
O
Research Center for Cellular and Molecular Neurobiology and Laboratory of Pharmacology, University of Liège, B-4000 Liège, Belgium.
Massotte
Laurent
L
Alleva
Livia
L
Graulich
Amaury
A
Thomas
Elizabeth
E
Liégeois
Jean-François
JF
Scuvée-Moreau
Jacqueline
J
Seutin
Vincent
V
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D000473:Alkanes / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D004298:Dopamine / Q000378:metabolism* / Q000494:pharmacology; D004347:Drug Interactions; D018756:GABA Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D007478:Iontophoresis / Q000379:methods; D007546:Isoquinolines / Q000494:pharmacology; D008297:Male; D008636:Mesencephalon / Q000166:cytology*; D018721:Muscarinic Agonists / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology*; D010095:Oxotremorine / Q000494:pharmacology; D011724:Pyridazines / Q000494:pharmacology; D011806:Quinolinium Compounds / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D051640:Small-Conductance Calcium-Activated Potassium Channels / Q000037:antagonists & inhibitors / Q000502:physiology*; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
C110349:6,10-diaza-3(1,3),8(1,4)dibenzena-1,5(1,4)diquinolinacyclodecaphane; D000473:Alkanes; D018756:GABA Antagonists; D007546:Isoquinolines; D018721:Muscarinic Agonists; D011724:Pyridazines; D011806:Quinolinium Compounds; D051640:Small-Conductance Calcium-Activated Potassium Channels; D005680:gamma-Aminobutyric Acid; D010095:Oxotremorine; C049853:gabazine; C001522:laudanosine; D004298:Dopamine